Modality
Small Molecule
MOA
CD47i
Target
PLK4
Pathway
Notch
DLBCLMyelofibrosis
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
Jan 2023
→ Mar 2031
Phase 1Current
NCT06940603
2,164 pts·DLBCL
2023-01→2031-03·Completed
2,164 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-135mo agoEnrollment Complete· Myelofibrosis
2031-03-024.9y awayInterim· DLBCL
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Complet…
Catalysts
Enrollment Complete
2025-11-13 · 5mo ago
Myelofibrosis
Interim
2031-03-02 · 4.9y away
DLBCL
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06940603 | Phase 1 | DLBCL | Completed | 2164 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |